We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Markers Found for Early Detection of Type 1 Diabetes

By LabMedica International staff writers
Posted on 20 Oct 2009
German researchers have identified new markers that enable an early diagnosis and prognosis of type 1 diabetes.

German scientist investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. More...
The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome. These high-risk individuals require especially careful monitoring.

The research was performed under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München (Germany) and Technische Universität München (Germany).

Worldwide, the number of children who develop type 1 diabetes is increasing. In Germany, approximately 11,000 children are affected. On average, they are eight and a half years old when they are diagnosed with the disease. However, already at this age many children show severe metabolic decompensation. Successful prevention strategies and detailed screening can prevent this.

Prof. Dr. Anette Ziegler and Dr. Peter Achenbach, from Helmholtz Zentrum München and Technische Universität München in cooperation with Prof. Dr. Ezio Bonifacio of Technische Universität Dresden, have developed a new approach to improve and extend risk screening. "Acute severe complications such as diabetic coma at disease onset can thus be avoided in the majority of the children,” Dr. Peter Achenbach explained. The scientists evaluated the data of 1,633 children who had at least one type 1 diabetic parent. These children's risk for diabetes was elevated in comparison with children who had no family history of diabetes.

Genetic factors play a considerable role in the development of type 1 diabetes. The scientists were able to show that specific variants of the zinc transporter gene SLC30A8 influence the risk for diabetes. The body needs this gene in order to produce ZnT8. This protein influences the zinc transport into the beta cells and plays a crucial role in their maturation and thus also in insulin secretion.

Beta cells of the islets of Langerhans in the pancreas secrete the critically important insulin. Already before the onset of type 1 diabetes the body's own immune system destroys the beta cells. If this destruction exceeds a certain threshold, the disease becomes evident: The insulin deficiency leads to various metabolic disturbances, including elevated blood glucose levels.

"Autoantibodies to ZnT8 in combination with a specific variant of the zinc transporter gene were associated with an elevated diabetes risk,” said Dr. Peter Achenbach, from the Institute for Diabetes Research at Helmholtz Zentrum München. "Eighty-one percent of these children with ZnT8 antibodies developed diabetes mellitus.” An increased diabetes risk has long been associated with the islet autoantibodies. These include the autoantibodies to insulin (IAA), islet cell antibodies to the enzyme glutamate decarboxylase (GADA) and to tyrosine phosphatases (IA-2A and IA-2ß).

"Autoantibodies to ZnT8 are an additional important marker for the progression of diabetes--especially in children who are already developing islet autoantibodies,” said Dr. Thomas Illig, from the Institute of Epidemiology at Helmholtz Zentrum München. A differentiated analysis of all autoantibodies allows the prognosis of how fast the disease will become manifest. According to Dr. Illig, the rule of thumb is: The larger the number of different kinds of autoantibodies, the higher the risk for diabetes, and the younger the child with autoantibodies, the earlier disease onset will be.

The study was published in the September 2009 issue of the journal Diabetolgia
Related Links:
Helmholtz Zentrum München
Technische Universität München





New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.